# A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

> **NCT05862233** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** MIL62
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT05862233
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-02
- **Primary completion:** 2025-05-13
- **Final completion:** 2026-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862233, "A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05862233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*